ESG Yields Important Weight Loss Throughout Weight problems Courses


Endoscopic sleeve gastroplasty (ESG) is secure and efficient for weight reduction in adults with class I, II, or III obesity, in line with real-world knowledge from a big US research.


  • Researchers carried out a retrospective evaluation of 1506 adults (85% feminine, 70% White) with extreme weight problems (501 class I, 546 class II, and 459 class III) who underwent ESG at seven tutorial and personal US facilities from 2013-2022.

  • Common % whole physique weight reduction (%TBWL) was evaluated at 6, 12, 18, and 24 months after the process.

  • Weight reduction and security outcomes have been evaluated in line with weight problems class.


  • At 12 months, 83.2% of sufferers achieved ≥10% TBWL and 60.9% achieved ≥15% TBWL throughout all weight problems courses.

  • There was a big distinction in TBWL by baseline weight problems class, with common weight reduction considerably higher at school III than courses I and II in any respect timepoints. At 24 months, class III sufferers had imply TBWL of 20.4%, in contrast with 13.3% for sophistication I and 13.6% for sophistication II sufferers.

  • As early as 6 months post-ESG, sufferers in all BMI courses have been in a position to drop to the following decrease BMI class and remained there by way of 2 years. Nevertheless, ongoing enchancment in BMI till the top of follow-up was seen solely at school III sufferers. Notably, class III sufferers have been considerably youthful and taller than class I and sophistication II sufferers.

  • There have been no variations in adversarial occasions between weight problems courses. Solely 2.6% of sufferers had an adversarial occasion requiring hospitalization. Most of those occasions (86%) have been for symptom administration and/or fluid alternative.


“Historically, ESG has been proposed as a therapy selection for sufferers with class I and II weight problems due to its modest weight reduction outcomes. Nevertheless, our knowledge present a %TBWL crossing 20% in sufferers with class III illness, which can push the envelope of perceived utility of ESG,” the authors write.


The research, with first creator Khushboo Gala, MBBS, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, was published online October 3 in Medical and Translational Gastroenterology.


Limitations embrace the retrospective design, with outcomes solely out to 2 years, and lack of follow-up, with solely 339 of the 1506 sufferers evaluated at 2 years.


The research had no monetary assist. A number of research authors reported ties to trade. The complete checklist could be discovered with the unique article.

For extra information, comply with Medscape on Facebook, X (formerly Twitter), Instagram, YouTube, and LinkedIn